Dr Fenske on ASCT Outcomes in MCL After First MRD-Negative CR
Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.
Related Articles
No Scientific Link Found Between Sickle Cell Trait and Sudden Death – Hematology.org
No Scientific Link Found Between Sickle Cell Trait and Sudden Death
Blood Test Can Detect Colorectal Cancer in Average-Risk Individuals
An investigational blood test can detect colorectal cancer (CRC) in patients at average risk of CRC, a study suggests.
Meta‐analysis of randomized controlled trials of external‐beam radiation versus transarterial chemoembolization for hepatocellular carcinoma
After performing a systematic review and meta-analysis of randomized controlled trials, the authors observed that external-beam radiation therapy produced superior local control and progression-free …
Editors’ Picks, January 2025: Evolutionary Insights Into Cancer, Impact of Nicotine Levels in E-cigarettes, and More
In January 2025, AACR’s 10 journals editors selected studies on nicotine levels in e-cigarettes, cancer prevenance across species, and more.
RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9‐year follow‐up
This is the first European study to show a safe screening interval of 9 years with messenger RNA (mRNA) human papillomavirus (HPV) Aptima testing with…
ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer
Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.
Final Program
Join us at #ACT2025 for an opportunity to engage deeply with the latest research, innovative techniques, and collaborative approaches that are shaping our practices. Please…
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Singapore Health Sciences Authority (HSA)
/PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of…
The present and future of the Cancer Dependency Map
Nature Reviews Cancer – The Cancer Dependency Map (DepMap) is a data repository and research platform that can be utilized to systematically identify cancer vulnerabilities.…
Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Association and ASCO Quality Training Program | JCO Oncology Practice
PURPOSEThe Hematology Oncology Pharmacist Association Oral Chemotherapy Collaborative (HOPA OCC) developed practice-based tools to use in program development and improvement for the management of patients…
